Buy this Article for $10.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


  1. Murphy, Elyse BSN, RN
  2. Vanname, Chris RN
  3. McNeill, Robert PharmD, MBA
  4. Bullock, Melody MS, BS, BSN, CRNI(R), IgCN
  5. Barrett, Lisa BSN, RN, CRNI(R), IgCN
  6. Kafal, Ayman PhD, MSc, MBA


Subcutaneous immunoglobulin (SCIg) is approved for maintenance treatment of chronic inflammatory demyelinating polyneuropathy. SCIg allows self-administration of immunoglobulin G and is associated with fewer systemic adverse events than intravenous administration. This study aimed to determine if patients with chronic inflammatory demyelinating polyneuropathy transitioning from intravenous administration of immunoglobulin G to SCIg improved their infusion parameters during training with the Specialty Pharmacy Nurse Network and identify factors impacting training and ongoing treatment optimization. Of the 310 patients analyzed, most improved their infusion parameters during training. Setting patient expectations and providing education on SCIg technique may improve patients' ability to reach optimal infusion parameters and encourage individualization.